H1 secures $40M from CVS, proving SaaS startups can still attract investment
H1 raised $40 million led by CVS Health Ventures after becoming cash-flow and EBITDA profitable. The deal shows some data-first SaaS startups can still draw capital even as AI dominates funding.
Intelligence analysis by GPT-5.4 Mini
H1, a nine-year-old healthcare data platform, raised $40 million from CVS Health Ventures despite a market that is largely favoring AI startups. The company says it is already profitable and growing, and it sees its physician data as hard for AI tools to replace.
H1 is like a giant address book for doctors that hospitals and drug companies use. It helps them find the right people and information faster.
A big healthcare company called CVS decided to put $40 million into H1. That is like a trusted partner buying a big stake in a company because it thinks the company solves a real problem.
The story matters because many people think only AI companies get money now. H1 shows that a company with special data and real customers can still get investors interested, even when the market is crowded.
Analysis
What happened
H1, a healthcare data platform founded nine years ago, raised $40 million in a round led by CVS Health Ventures, the corporate venture arm of CVS/Aetna. The company was not actively fundraising, but CEO Ariel Katz said the partnership with a major healthcare player made the deal attractive.
Why H1 thinks it can win
Katz argues that not all SaaS businesses face the same pressure from AI. In his view, workflow software can be easier to copy with AI tools, but a company centered on proprietary data is harder to replace. H1 sells detailed physician information to pharma companies, hospital systems, and health insurers, and Katz said he does not expect Claude or other AI models to do the same work.
Business context
H1 says it turned cash-flow and EBITDA profitable last year and is forecasting more than 40% growth this year. The startup was last valued at $750 million in 2021, when it raised $100 million led by Altimeter Capital near the peak of the Covid-era tech bubble. Like many companies that raised before valuations fell in 2022, H1 has since focused on profitability and on buying smaller competitors and adjacent businesses.
Why it matters
The article frames H1 as a counterexample to the idea that only AI startups can attract serious capital right now. It also shows how strategic corporate investors can still back software businesses when the product fits their ecosystem and the startup has defensible data and improving financials.
Key points
- CVS Health Ventures led a $40 million round in H1.
- H1 says it was already cash-flow and EBITDA profitable before the raise.
- CEO Ariel Katz argues data-heavy SaaS is harder for AI to replace than workflow software.
- H1 was last valued at $750 million in 2021, during the Covid-era tech boom.
- The company has also grown by acquiring smaller competitors and related businesses.
